Galectin 9, CXCL-10 and tumor necrosis factor receptor type II as biomarkers of disease activity in systemic lupus erythematosus - 08/05/22
Doi : 10.1016/j.jbspin.2021.105311
Noémie Gensous a, b, 1, Damien Vagner c, 1, Thomas Barnetche d, Pierre Duffau a, b, Estibaliz Lazaro b, e, Christophe Richez b, d, Patrick Blanco b, c, ⁎ 
a Department of Internal Medicine and Clinical Immunology, Bordeaux University Hospital (Groupe Hospitalier Saint-André), Bordeaux, France
b UMR/CNRS 5164, ImmunoConcEpT, CNRS, University of Bordeaux, Bordeaux, France
c Laboratory of Immunology and Immunogenetic, Bordeaux University Hospital (Groupe Hospitalier Pellegrin), Place Amélie Raba Léon, Bordeaux, France
d Rheumatology department, FHU ACRONIM, Reference Center of rare auto-immune systemic diseases, Bordeaux University Hospital, Bordeaux, France
e Department of Internal Medicine and Infectious Diseases, CHU Bordeaux (Groupe Hospitalier Haut Leveque), Pessac, France
⁎Corresponding author at: Laboratory of Immunology and Immunogenetic, Bordeaux University Hospital (Groupe Hospitalier Pellegrin), Place Amélie Raba Léon, Bordeaux, France.Laboratory of Immunology and Immunogenetic, Bordeaux University Hospital (Groupe Hospitalier Pellegrin)Place Amélie Raba LéonBordeauxFrance
Highlights |
• | CXCL-10, TNF-RII and GAL-9 levels were greater in SLE patients than in healthy controls. |
• | Their levels were higher in SLE patients with active disease than in patient with a quiescent one. |
• | Their concentrations correlated significantly with SLEDAI scores, anti-dsDNA antibodies and C3 levels. |
Keywords : Systemic lupus erythematosus, Disease activity, Biomarkers, Interferon signature, Galectins
Plan
© 2021
Société française de rhumatologie. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89 - N° 3
Article 105311- mai 2022 Retour au numéro
Article précédent
- Clinical characteristics and resource utilization of 19,130 hospitalizations of patients with ankylosing spondylitis in United States: National Inpatient Sample 2018
- Patompong Ungprasert, Thanat Chaikijurajai, Karn Wijarnpreecha, Paul T. Kröner
- Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry
- Adeline Ruyssen-Witrand, Yacine Boudali, Isabelle Pane, Alain Cantagrel, Pascale Thevenot, Martin Soubrier, Jacques Morel, Eric Houvenagel, Alain Saraux, André Basch, Marie-Elise Truchetet, Hubert Marotte, Emmanuelle Dernis, Pascal Claudepierre, René-Marc Flipo, Jacques-Eric Gottenberg, Philippe Ravaud, Xavier Mariette, Raphaele Seror
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?